BioLineRx Ltd. (BLRX)

Nasdaq: BLRX · Pharmaceutical Preparations · filing with the SEC since 2010

Full chart Alerts Compare

Grade4.2

◀ Past 4.2● Present 4.3▶ Future 4.1

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of BioLineRx Ltd.

Nine metrics read from its own filings, by tense

Headline grade

4.2/10

◀ Past4.225% of the headline

● Present4.335% of the headline

▶ Future4.140% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

4.2/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

8.2/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 22% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

BioLineRx Ltd.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

3.0/10

What has it actually done, year after year?

5 filed years; profitable in 0 of 5.

weight 45% of this tense · 30th percentile among 323 sector filers · read for its customers

From the record

BioLineRx Ltd.'s 5 filed years say what it did: it rose in 1 of 2 years; the deepest fall was 96% from fiscal 2024 to fiscal 2025; net income was positive in 0 of 5 of those years (its annual reports).

What it rests on

the share of years revenue rosebottom 36% of its family
the share of filed years with a profitbottom 27% of its family
the deepest fall from a revenue peak95.9%bottom 28% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

3.2/10

How has it treated the people who own it?

SI estimate 3.2/10, confidence 35 of 100 (one part).

weight 33% of this tense · 32nd percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 32% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: BioLineRx Ltd.'s shareholder treatment is put at 3.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 32% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.3/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed

4.1/10

Is it financially healthy right now?

ROE -9%: lost 9¢ per shareholder dollar. Leverage 43%: owes 43¢ per asset dollar.

weight 45% of this tense · 41st percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, BioLineRx Ltd. lost about 9 cents for every dollar of shareholders' money, and gross profitability: its products earned about 2 cents per dollar of everything the company owns. Leverage: it owed about 43 cents per dollar of assets, and net share issuance: its share count grew 105.8% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 40% of its family
return on equitytop 20% of its family
gross profit against assetsbottom 18% of its family
the share count against the year beforebottom 24% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

3.6/10

How strong is its position in its industry?

bottom 36% of 315 in its family; net margin -171.7%.

weight 22% of this tense · 36th percentile among 315 sector filers · read for its customers

From the record

BioLineRx Ltd.'s standing among 315 graded names in its industry family: revenue of $1 million in fiscal 2025 ranks in the bottom 24% by size; a net margin of -171.7% ranks in the bottom 48% (its annual reports).

What it rests on

revenue against the family$1.2Mbottom 24% of its family
net margin-171.7%bottom 48% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate

5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 371 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one.
What the record cannot read: It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned: family median, 371 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: BioLineRx Ltd.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2026-03-18 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 8 months and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 371 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

4.1/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed

4.9/10

How much room does it have to grow?

bottom 49% of 273 in its family for room to expand.

weight 33% of this tense · 49th percentile among 273 sector filers · read for itself

From the record

BioLineRx Ltd.'s room to grow, from the newest filed statements (fiscal 2025): cash of $3 million against no long-term debt tagged leaves 7.9% of its assets as net cash, bottom 22% of its family; cash from operations less capital spending is -686.4% of revenue (bottom 30%); a gross margin of 80.5% (top 33%); research spending of 685.8% of revenue (top 24%) (its annual report).

What it rests on

cash less debt against assets7.9%bottom 22% of its family
cash from operations less capital spending against revenue-686.4%bottom 30% of its family
gross margin80.5%top 33% of its family
research spending against revenue685.8%top 24% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

1.6/10

What could actually drive growth from here?

bottom 16% of 306 in its family for growth drivers.

weight 45% of this tense · 16th percentile among 306 sector filers · read for its customers

From the record

BioLineRx Ltd.'s growth drivers, from the filed years to fiscal 2025: the newest year grew -95.9% (bottom 2%); research spending grew -22.9% a year (bottom 18%); capital spending grew -42.4% a year (bottom 27%) (its annual reports). BioLineRx Ltd. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

the newest year's revenue growth-95.9%bottom 2% of its family
three-year growth of research spending-22.9%bottom 18% of its family
three-year growth of capital spending-42.4%bottom 27% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

8.1/10

Did its newest year beat what its own record pointed to?

top 19% of 233 in its family for expectations against reality.

weight 22% of this tense · 81st percentile among 233 sector filers · read for its shareholders

From the record

BioLineRx Ltd.'s newest year against its own record: net income of $2 million against a prior three-year average of $32 million (top 17%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 21%) (its annual reports).

What it rests on

net income against the prior three years' average+94%top 17% of its family
net margin against its prior averageup more than 100 pointstop 21% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton BLRX · research, not advice